| Literature DB >> 30554455 |
Yifan Meng1, Gaoli Fang2, Xiangdong Wang1, Xiaohong Song1, Kuiji Wang1, Hongfei Lou1, Wenyu She3, Long Qin4, Mei Lv5, Tao Zhang6, Tiejun Yuan7, Yanli Tao7, Xun Meng6, Luo Zhang1,3,8, Chengshuo Wang1.
Abstract
BACKGROUND: We aimed to assess the recurrence risk of sinonasal inverted papillomas (SNIPs), based on a staging system developed according to the originating site of SNIP.Entities:
Keywords: endoscopy; recurrence; sinonasal inverted papilloma; staging system; surgical approach
Mesh:
Year: 2018 PMID: 30554455 PMCID: PMC6590184 DOI: 10.1002/hed.25435
Source DB: PubMed Journal: Head Neck ISSN: 1043-3074 Impact factor: 3.147
Figure 1Cluster analysis of data for 200 patients enrolled in the preliminary study from March 2000 to March 2007. Four clusters were determined based on recurrence rates for different anatomical regions. NC, nasal cavity; ES1, ethmoid sinus (except superior orbital cell); MS1, posterior, lateral, or superior wall of the maxillary sinus; SS1, sphenoid sinus (medial of Sternberg's canal); FS1, frontal sinus (facial midline to lamina papyracea); ES2, superior orbital cell; MS2, inferior, anterior, or medial wall of the maxillary sinus; SS2, sphenoid sinus (lateral of Sternberg's canal or affected bilateral sinus); FS2, frontal sinus (lamina papyracea to central pupil or invading bilateral sinus); FS3, frontal sinus (lateral of central pupil)
The sinonasal inverted papilloma staging system and recommended surgical approach
| Classification based on the originating site | Recommended surgical approach | |
|---|---|---|
| Stage 1 | Nasal cavity | ESS (simple tumor resection) |
| Stage 2 | Ethmoid sinus (except superior orbital cell) | ESS |
| Posterior, lateral, or superior wall of the maxillary sinus; sphenoid sinus (medial of Sternberg's canal); frontal sinus (facial midline to lamina papyracea) | ||
| Stage 3 | Superior orbital cell | ESS‐assisted endonasal approach (ie, Draf IIb approach plus lamina papyracea resection) |
| Inferior, anterior, or medial wall of the maxillary sinus; sphenoid sinus (lateral of Sternberg's canal) | ESS‐assisted prelacrimal duct approach | |
| ESS‐assisted pterygoid process approach | ||
| Sphenoid sinus (invading bilateral sinus) | ESS‐assisted sphenoidal rostrum process approach | |
| Frontal sinus (lamina papyracea to central pupil or invading bilateral sinus) | Draf IIb approach plus lamina papyracea resection or ESS‐assisted Draf III approach | |
| Stage 4 | Frontal sinus (lateral of central pupil) | ESS with combined external approach |
Abbreviation: ESS, endoscopic sinus surgery.
Figure 2Schematic diagram showing the endoscopic staging system of sinonasal inverted papilloma (SNIP), based on the tumor origin sites. (A) Stage 1: origin site located in nasal cavity; (B) stage 2: origin site located in ethmoid sinus (except superior orbital cell) and superior wall of the maxillary sinus; (C) stage 2: origin site located in lateral, posterior wall of the maxillary sinus; (D) stage 2: origin site located in sphenoid sinus (medial of Sternberg's canal); (E) stage 2: origin site located in frontal sinus (facial midline to lamina papyracea); (F) stage 3: origin site located in the superior orbital cell or inferior wall of the maxillary sinus; (G) stage 3: origin site located in anterior or medial wall of the maxillary sinus; (H) stage 3: origin site located in sphenoid sinus (lateral of Sternberg's canal); (I) stage 3: origin site located in sphenoid sinus septum and bilateral sinus; (J) stage 3: origin site located in frontal sinus (lamina papyracea to central pupil); (K) stage 3: origin site located in bilateral fontal sinus and break through the frontal sinus septum; (L) stage 4:origin site located in frontal sinus (lateral of central pupil)
The characteristics of different stage
| Stage 1 | Stage 2 | Stage 3 | Stage 4 |
| |
|---|---|---|---|---|---|
| Case | 43 | 420 | 134 | 11 | |
| Age (mean ± SD), years | 45.7 ± 7.4 | 50.7 ± 7.1 | 50.0 ± 4.3 | 53.1 ± 3.8 | NS |
| Sex (M/W) | 29/14 | 381/39 | 113/21 | 8/3 | <.001 |
| Recurrence cases (%) | 0 (0) | 17 (4.0) | 18 (13.4) | 4 (36.4) | <.01 |
Abbreviations: M, men; W, women.
SNIP originating site located in sinuses based on the staging system employed
| Classification based on: | ||
|---|---|---|
| SNIP originating site (%) | Krouse Classification | |
| Stage 1 | 43 cases | 23 cases |
| Stage 2 | 420 cases | |
| 97 in maxillary sinus (23.1) | 322 cases | |
| 255 in ethmoid sinus (60.7) | 68 in maxillary sinus (21.1) | |
| 38 in frontal sinus (9.0) | 254 in ethmoid sinus (78.9) | |
| 30 in sphenoid sinus (7.1) | ||
| Stage 3 | 134 cases | |
| 72 in maxillary sinus (53.7) | 245 cases | |
| 29 in frontal sinus (21.6) | 109 in maxillary sinus (44.5) | |
| 19 in sphenoid sinus (14.2) | 71 in frontal sinus (29.0) | |
| 14 in superior orbital cell (10.4) | 65 in sphenoid sinus (26.5) | |
| Stage 4 | 11 cases | 18 cases |
| 11 in frontal sinus | ||
Figure 3Survival analysis of the study cohort. The recurrence‐free survival rates of stages 1‐4 were 100% (black line), 96.0% (92.4%‐98.1%, pink line), 86.6% (83.1%‐94.7%, blue line), and 63.6% (56.7%‐70.7%, red line), respectively (95% confidence interval, P < .05)